Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I sold last time at .085 and got back in at .02, this stock moves quick!!!!!
I was here back when I got shares around .015 and we ran into the high .20's
Newtechinvestor and I were the only two here back then. (LOL)
The last run was much smaller because it was all put off for a year so I sold and watched. Been adding here and there and hoping this will give us news early in 2012.
At least we getting some posts!!!!!!!, I thought for a while the board was BROKEN!
True, but 80,000 were at .038 on this day. http://investorshub.advfn.com/boards/read_msg.aspx?message_id=67771261
Up 52% today! WOW..... too bad the volume was 2000 shares....LOL
Was in a car accident about 8 months ago and was in a coma for 7 of those months, upon awakening I checked the stock price and it was exactly the same. LOL
Well, we're little yellow bus special.
This stock is sooooo boring. LOL
Hey Super...I hope you haven't forgotten us here. =P
Oh, oh, me too, mmeeeee tttoooooooooo.
Almost 100K today with quite a few takings us to .038-.04 and ending the day at .03 so no one will notice the % move because it's down then. (LOL)
Cool, wish they present to me $1.00/share! :)
price ticking up here lately.......
Just got back in 30K @ .03 looking to add more later.
AVAX Technologies, Inc. Files Amendment No. 1 to Form 10 on May 5, 2011
http://www.sec.gov/Archives/edgar/data/1015441/000114420411026242/v219857_10-12ga.htm
Your welcome, looks like the BID upticked on that news a bit
much obliged.
What Does SEC Form 10-12G Mean?
A filing with the Securities and Exchange Commission (SEC), also known as the "Initial Form for General Registration of Securities", required when a publicly traded corporation issues new shares of a company's stock. SEC Form 10-12G contains information about the number of shares issued, their par value, ownership information for key shareholders and executives, and specific information about the company's line of business.
Investopedia Says
Investopedia explains SEC Form 10-12G
SEC Form 10-12G is one of the starting points for anyone wishing to truly research a company's stock. Contained on this form is information that can provide key insights into a management team's long-term direction for a company and assessment of potential risks and opportunities in their industry. Of additional interest to many investors is the fact that SEC Form 10-12G contains a breakdown of shares owned by company officers, giving insight into possible conflicts of interest underlying different executives' decisions.
http://www.investopedia.com/terms/s/sec-form-10-12g.asp
I'm no expert but it appears they were going to issue shares and decided not to.
sorry.
not to be a tool, but can someone translate?
Nice Find, Thanks
RW for AVAX TECHNOLOGIES INC
http://www.sec.gov/Archives/edgar/data/1015441/000114420411019964/v216782_rw.htm
Not to burst anybody's bubble but, as per Form 10, they are at least one year and $6.5 million in additional funding away from Ovax PhaseII trial results. After that, more years and at least $50 million in funding for final approval of either Mvax or Ovax.
So, this reaching over $1 anytime soon is unrealistic IMO.
Picked up 4k at 0.07 months ago because I hope it will be good.
Avax Tech(AVXT) 0.08 UP 0.01 (33.33%) Volume:681,717
Maybe won't get that pullback I was looking for to add some shares.....
I am going to add more on any pullback, I need more exposure on this one! Check out the new AVXT INTRO MESSAGE, I updated it over the weekend! ;O)
Avax Tech (AVXT)0.07 UP 0.01 (16.67%) / Volume: 579,887
The volume appears to be returning as more people are looking at this stock! ;O)
Things are starting to warm up with AVXT, so don't give up yet on this board! See NEW News!
http://ih.advfn.com/p.php?pid=nmona&article=46313256
Goodbye PINKSHEETS? Hello OTCBB?
AVAX Technologies, Inc. Files Form 10 With SEC
http://ih.advfn.com/p.php?pid=nmona&article=46313256
Bring it on!
GREAT FIND!, Keep up the Good DD. I just became moderator today so will take me some time to get the board together and do more extensive DD. I actually picked up mine some time ago under .03
There is some big players that have high hopes for the clinical trials and the company, I'd like to be along for the ride! :)
More than 90% of the shares are in hands of institutions!!!!
Firebird Global Master Fund, Ltd. and affiliates(4)
/c/ Trident Trust Company (Cayman) Limited
One Capital Place, P.O. Box 847
George Town, Grand Cayman KY1-1103
Cayman Islands
==> 80,49%
JFE Hottinger & Affiliates(5)
Hottingerstrasse 21
CH-8032 Zurich
Switzerland
==> 9,94%
page 54
http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=7694192
Welcome aboard then!
I'm in for about the same amount. Hoping it will get off the "pinkies" to add & buy into strength.
I checked their website earlier, was still being updated. We should know more in the coming weeks.
my order got filled... I expect that their website will be online next week. 10K shares at .06, not much, but when everything turns in favour, it'll be soon above a couple of dollars!
This stock is tough to figure out as it is a very low volume stock, probably just a "sell on the news" type event. We will see how things go to get off the pinksheets. Should see more volume if it does go through.
this seems good.
why the drop?
Product Candidates
http://en.wikipedia.org/wiki/Avax_Technologies
MVax
Started May 2007. Currently in a Phase III trial for Stage IV Melanoma.
MVax’s Phase II response rate of 35% (CR + PR) in combination with low-dose IL-2 compares favorably to the Phase II results of other melanoma cancer vaccines such as Vical’s Allovectin-7 (11% CR + PR)[2] and BioVex’s OncoVex (28% CR + PR)[3], both of which are given as stand alone therapy.
Due to the Financial crisis of 2007–2010 and recent cancer vaccine failures in other companies like Favrille and Cell Genesys, Avax has had trouble attracting investors. In an effort to conserve cash, enrollment for the Phase III trial was suspended on March 26, 2009[4], but the trial itself is still ongoing. However on December 16, 2009, the company obtained bridge financing in the amount of $1,400,000. This will be used to conduct an interim analysis of the Phase III data for MVax. CEO John Prendergast notes: "Recent and anticipated news by companies involved with cancer vaccines and immunotherapies has resulted in renewed interest in the sector by institutional investors, larger pharma, biotechnology companies and the medical and scientific communities at large."[5].
[edit] LVax
Started February 2006. Currently in a Phase I/II trial for NSCLC. No new patient enrollment until more funding is obtained.
[edit] OVax
Started April 2008.Currently in a Phase I/II trial for Ovarian Cancer.No new patient enrollment until more funding is obtained.
[edit] Genopoietic SA
Based in Lyon, France?,Genopoietic has a GMP facility that manufactures the vaccines for Avax. The facility is certified by the French government for commercial and clinical vaccine production for the European markets[1].
AVAX TECHNOLOGIES INC (AVXT)
Type Public
Industry Biomedicine
Headquarters Philadelphia, Pennsylvania, USA
Key people John Prendergast, Ph. D (Chairman and CEO)
Products AC Vaccine
Services Cancer vaccines
Subsidiaries Genopoietic SA
Website
http://www.avax-tech.com/
Avax Technologies, Inc (Pink Sheets: AVXT) is a Philadelphia based biotechnology company whose most advanced product candidate is MVax for melanoma. MVax is a cancer vaccine that received a Special Protocol Assessment agreement with the FDA in October 2006, and subsequently began a Phase III registration clinical trial in November 2007 [1]. In previous studies, MVax demonstrated a 5-year overall survival rate (OS)of 44% and response rate of 35% (13% CR, 22% PR)[1].
AVAX Technologies, Inc. Files Form 10 With SEC
http://www.prnewswire.com/news-releases/avax-technologies-inc-files-form-10-with-sec-115293279.html
PHILADELPHIA, Feb. 4, 2011 /PRNewswire/ -- AVAX Technologies, Inc. (Pink Sheets: AVXT) ("AVAX" or the "Company") today announced that it filed a Form 10 with the Securities and Exchange Commission ("SEC"). Upon the effectiveness of this Form 10, AVAX will once again become a publicly reporting company. The Company intends to seek to have its common stock trade on the Over-the-Counter Bulletin Board. The Company's Form 10, which contains among other things, recent information about the Company's business, operations, financial results and capitalization, can be accessed through the website maintained by the SEC at www.sec.gov.
About AVAX Technologies, Inc.
AVAX Technologies, Inc. is a biotechnology company headquartered in Philadelphia, PA. The Company is engaged in the research and clinical and commercial development of biological products and cancer therapeutics. The Company's AC Vaccine platform is a therapeutic cancer vaccine.
Forward-Looking Statements
Certain statements in this release are "forward-looking" statements. Forward-looking statements involve significant risks and uncertainties, and in light of the significant uncertainties inherent in such statements, the inclusion of such information should not be regarded as a representation by the Company that the objectives and plans of the Company will be achieved. In fact, actual results could differ materially from those contemplated by such forward-looking statements. These statements include, but are not limited to, the Company's immediate need to obtain additional funding to continue to finance the Company, the Company's plans, objectives, projections, expectations and intentions such as those relating to the future development of M-VAX® and its other vaccine candidates, as well as other important factors discussed in the Company's Form 10. The Company does not undertake any obligation to release publicly any revisions to these forward-looking statements or to reflect the occurrence of unanticipated events.
SOURCE AVAX Technologies, Inc.
Files Form 10 w/ SEC.....
...read on
http://www.sec.gov/Archives/edgar/data/1015441/000114420411005836/v206526_10-12g.htm
;)
Yes, this definitely has never been an I-hub stock ... and that's probably a good thing.
Wow --- Dead board. ZZZZZZZZZZZZZzzzzzzzzzzzzz
Followers
|
34
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1605
|
Created
|
05/25/05
|
Type
|
Free
|
Moderators |
Industry Center - Biotechnology
Contact Information | |
Address: | 2000 Hamilton St., Ste. 204 Philadelphia, PA 19130 |
Phone: | 215-241-9760 |
Fax: | 215-241-9684 |
Key People | |
• | CEO: Adele Sommerfeld |
• | BOD: Andrew W. Dahl Sc.D.; Serge Morrell |
| |||
|
Business Summary |
---|
AVAX Technologies, Inc., a development stage biotechnology company, together with its subsidiaries, engages in the development and future commercialization of individualized vaccine therapies and other technologies for the treatment of cancer in the United States and Europe. The company's autologous cell vaccine candidates include M-Vax under Phase III clinical status, which is used for the treatment of melanoma; L-Vax under Phase I-II clinical status that is used for the treatment of non-small cell lung cancer; and O-Vax under Phase I-II clinical status, which is used for the treatment of ovarian cancer. It also offers biological manufacturing services to other biotechnology and pharmaceutical companies; and contract manufacturing services in for cell and gene therapy, and biological products in France. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.
PHILADELPHIA, Feb. 4, 2011 /PRNewswire/ -- AVAX Technologies, Inc. (Pink Sheets:AVXT.pk - News) ("AVAX" or the "Company") today announced that it filed a Form 10 with the Securities and Exchange Commission ("SEC"). Upon the effectiveness of this Form 10, AVAX will once again become a publicly reporting company. The Company intends to seek to have its common stock trade on the Over-the-Counter Bulletin Board.
The Company's Form 10, which contains among other things, recent information about the Company's business, operations, financial results and capitalization, can be accessed through the website maintained by the SEC at www.sec.gov.
About AVAX Technologies, Inc.
AVAX Technologies, Inc. is a biotechnology company headquartered in Philadelphia, PA. The Company is engaged in the research and clinical and commercial development of biological products and cancer therapeutics.
The Company's AC Vaccine platform is a therapeutic cancer vaccine.
Forward-Looking Statements
Certain statements in this release are "forward-looking" statements. Forward-looking statements involve significant risks and uncertainties, and in light of the significant uncertainties inherent in such statements, the inclusion of such information should not be regarded as a representation by the Company that the objectives and plans of the Company will be achieved. In fact, actual results could differ materially from those contemplated by such forward-looking statements. These statements include, but are not limited to, the Company's immediate need to obtain additional funding to continue to finance the Company, the Company's plans, objectives, projections, expectations and intentions such as those relating to the future development of M-VAX® and its other vaccine candidates, as well as other important factors discussed in the Company's Form 10. The Company does not undertake any obligation to release publicly any revisions to these forward-looking statements or to reflect the occurrence of unanticipated events.
Press Releases & AVAX Information:
https://en.wikipedia.org/wiki/Avax_Technologies
http://www.reuters.com/article/2014/01/08/ctca-trial-cancer-idUSnPnDChVKwJ+16d+PRN20140108
http://ih.advfn.com/p.php?pid=nmona&article=61013370
http://www.bizjournals.com/philadelphia/blog/health-care/2014/02/ovarian-cancer-vaccine-testing-expands.html
http://www.avax-tech.com/about/pdfs/avaxfactsheet.pdf
Published: Aug 4, 2015 7:31 p.m. ET
PHILADELPHIA, Aug 04, 2015 (BUSINESS WIRE) -- AVAX Technologies, Inc., (“AVAX” or “The Company”) (AVXT – OTCMKTS), a leading developer of proprietary cancer immunotherapy products, has signed a Settlement & Release Agreement with Cancer Treatment Centers of America Inc. (“CTCA”) to positively resolve the existing debt obligations owed to CTCA.
Under the terms of the Settlement Agreement, CTCA has agreed to settle its $5,826,464.73 Judgment against AVAX in exchange for 860,000 Series A Convertible Preferred Shares at a consideration of $5.00 per share, and a one-time payment of $1.5 million in cash. Firebird Management, a shareholder and a creditor of AVAX, has agreed to swap its outstanding debt for the Series A Convertible Preferred Shares also at a consideration of $5.00 per share.
Andrew Dahl, AVAX Board Member noted, “we are extremely happy to be able to move forward with the reorganization of AVAX’s balance sheet and look forward to re-commencing the important planned clinical trials at AVAX. Our previous work with CTCA on clinical programs has been very successful.”
Richard Rainey, Acting Chief Executive Officer of AVAX, stated, “We are pleased that throughout the development of our AC Vaccine® platform, all of our data has remained consistently positive and has supported further development of the treatment. We feel our immunotherapy platform is consistent with recently approved products and could be additive to the benefits achieved in helping patients with cancer.”
SGC Canada Inc., is acting on behalf of AVAX with its creditors in negotiating its informal restructuring plan. David Holden, the Senior Corporate Advisor of SGC states that “AVAX will be effectively debt-free once the Financial Restructuring & Refinancing Plan is completed.” The Board of AVAX has previously approved the engagement of Phoenix Corporate Finance Inc., a corporate finance firm which specializes in alternative financing, to advise, structure, and facilitate the distribution of a proposed Private Placement financing. through select securities dealers in the US and Canada. AVAX intends to raise $45 million to fund its next round of clinical testing through the issuance of the Series A Convertible Preferred Shares.
AVAX TECHNOLOGIES WEBSITE IS NOW ACTIVE: WWW.AVAX-TECH.COM/
AVAX TECHNOLOGIES, INC APPOINTS NEW CEO: ADELE SOMMERFELD 10/19/2015
http://www.prnewswire.com/news-releases/avax-technologies-inc-announces-the-appointment-of-chief-executive-officer-300161646.html
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |